Lignocaine has been shown to reduce the incidence oj pain on injection oj propojol. Metoc!opramide, a weak local anaesthetic and commonly used antiemetic, was combined with propojol and the mixture compared, in a prospective, randomized trial, with a lignocaine-propojol combination. The incidence oj injection pain was similar in both groups, as were recovery times and incidence oj vomiting. The metoc!opramide-propojol group experienced a lower incidence oj nausea. One patient in the metoc!opramide-propojol group had a minor extrapyramidal reaction. No adverse local or haemodynamic ejjects were seen.
Propofol possesses many attractive properties, especially for brief cases and where a laryngeal mask is to be used l ". However up to 30% of patients complain of pain during induction 3 • Injection pain with propofol is experienced more frequently by the unpremedicated patient, and when the drug is introduced via small veins 3 • Various strategies have been advocated to reduce injection discomfort, including the preparation of the skin prior to venepuncture with nitroglycerine ointment., the use of cold propofol5 or giving the drug via large antecubital veins or into a freely flowing intravenous line], 6 . The most effective technique may be the addition of a small dose of lignocaine (typically 10 to 15 mg) to the injectate 7 ,R.
Metoclopramide (2-methoxy-5-chloroprocainamide) shares structural and physico-chemical properties with lignocaine", and is a weak local anaesthetic in its own right iO. In clinical anaesthetic practice metoclopramide has been shown to reduce the early incidence of nausea and vomiting, particularly in minor gynaecological surgery, to enhance gastric emptying and lower oesophageal sphincter tone, and to increase both the frequency and amplitude of oesophageal peristalsis". Potentiation of opioid analgesics has been reported I \ as has reduction of thiopentone induction dose l '. Adverse effects are infrequently seen with conventional doses, and are usually extrapyramidal in origin. Opisthotonos may occur in up to 1070 of young patients l3 . Hypertensive crisis has been reported in association with phaeochromocytoma l4 and is a possible interaction where monoamine oxidase inhibitors (MAOIs) are used'.
Ganta and Fee l5 have shown that the pretreatment of small veins with 5 mg metoclopramide may reduce the pain reported by premedicated patients when propofol is subsequently used for induction.
A prospective, randomized, double-blind trial was conducted in unpremedicated patients to determine if injection pain could be reduced by adding metoclopramide rather than lignocaine directly to propofol emulsion. Adverse local, haemodynamic, and sedative effects were assessed, as was the incidence of nausea and vomiting.
MATERIALS AND METHODS
Ethics Committee approval was obtained to conduct the trial, and all patients gave their informed consent prior to enrolment. Subjects were 100 ASA grade 1 or 2 adults, presenting for minor surgery at a regional hospital. Those taking sedative or analgesic agents or with a history suggestive of previous adverse effects from any of the study drugs were excluded. No premedication was given.
Patients were randomly assigned to be induced with a mixture of room temperature propofol 200 mg to which was added either 20 mg metoclopramide (total volume 24 ml) or 1 ml of 1070 lignocaine (10 mg) and 3 ml normal saline (total volume 24 m!). Drugs were prepared by a study assistant who took no further active part in the trial. Both patient and anaesthetist were blinded to the content of the induction syringe. Drugs were used within an hour of preparation and there was no attempt to agitate the syringe after initial mixing.
After application of conventional monitoring devices and establishing baseline haemodynamic values, a 22 gauge intravenous cannula (Surflo, Terumo, Japan) was sited on the dorsum of the patient's non-dominant hand, and free backflow of blood demonstrated.
A test dose of 2.0 ml of the induction mixture was given over four seconds without questioning the patient about discomfort. Any unprompted response was noted and scored on a four point scale: 0 = no comment, 1 = minimal discomfort (e.g. "warm"), 2=moderate discomfort, 3 = severe pain. For a score of 3, 1.0 ml of 1070 lignocaine was added to the injectate as a rescue measure and the test dose repeated. Thirty seconds after the test dose, induction commenced at a rate of 1.0 mllsec of the injectate. When 10 ml had been given, the patient was directly questioned about unpleasant sensations, which were scored as above. Any significant pain at this time was treated by a rapid bolus of injectate (5 ml). Further conduct of the case was at the discretion of the anaesthetist.
Blood pressure was measured three minutely and haemodynamic disturbance was recorded if mean blood pressure or pulse rate varied more than 30% from preinduction values, or a rhythm other than sinus observed. Local adverse effect was defined as erythema > 1 cm at the cannula site or tenderness along the vessel noted prior to removal of the cannula. Extrapyramidal effects were noted where peripheral tone was felt to be increased, the subject complained of stiffness, or jaw tone precluded LMA insertion.
Recovery times were recorded as 1. time to removal of LMA or spontaneous eye opening, 2. time when assessed as fit to leave recovery suite. At time 2. subjects were directly questioned regarding nausea, and any vomiting noted. Lastly subjects were asked if they found induction pleasant or unpleasant, and whether they would have the same induction agent for future procedures.
Inter-group differences were analysed using the Mann-Whitney U test for ordinal data and Chi-squared with Yates correction or Fisher's exact test for dichotomous data. Summary variables including demographic data were analysed with unpaired, two-tailed t-test, or Fisher's exact test. P<0.05 was taken as significant.
RESULTS
The two groups were similar with regard to age, weight, sex and ASA status. The female bias reflects enrolment in the day surgery unit. Many of these patients presented for minor gynaecological procedures.
Initial pain scores were similar, whether subjects received metoclopramide or lignocaine mixed with propofol. A single patient in the metoclopramide-Anaesthesia and Intensive Care, Vol. 22, No. 5, October, 1994 propofol group had an initial pain score of 3. Lignocaine was added as a rescue measure. Her subsequent scores were 1 (second test dose at 30 seconds) and 2 (after 10 ml).
Number
Age Weight (kg) Female Gynaecology ASA 112 
39/13
No difference in pain score on direct inquiry was found. (Mann-Whitney U statistic = 1228, P=0.89.) In the lignocaine-propofol group 22 patients recorded a score other than 0, as did 14 in the metoclopramidepropofol group. Two patients in this latter group had scores of 3 ( Table 2) . Recovery times were similar in the two groups. Mean time to open eyes or LMA removal was 6.8 min (SD 4.9) in the metoclopramide-propofol group, and 8.7 min (SD 7.4) in the lignocaine-propofol group. The corresponding "fit to leave" times were 26.2 min (SO 19.9) and 29.3 min (SO 24.6). Four patients in each group were not considered fit to leave for over an hour.
A single patient in the metoclopramide-propofol group was noted to be hypertonic after induction. She received 0.4 mg/kg metoclopramide, and her tone was judged to be normal after five minutes of spontaneously breathing isoflurane. No adverse haemodynamic or local effects were observed.
There was a significantly lower incidence of nausea in the metoclopramide-propofol group (Chi-squared with Yates correction = 7.53, OF = 1. P=0.006). There was no inter-group difference in the incidence of vomiting (Chi-squared with Yates correction = 0.35, OF = 1, P=0.55) ( Table 3 ). Nausea Vomiting All patients indicated that induction was pleasant and that they would have the same anaesthetic in the future.
DISCUSSION
The mechanism by which propofol causes pain on injection remains obscure, but probably involves an interaction between the active component of the emulsion and the vascular endothelium 3 • Lignocaine has been repeatedly demonstrated to substantially reduce propofol injection pain, and the addition of lignocaine to propofol immediately prior to induction is common 4 .'.7,8. It was felt unethical to include a saline (or similar) control group in the present study because patients randomized to this group could be expected to experience unnecessary discomfort.
Metoclopramide pretreatment (5 mg via a 23 gauge cannula) has previously been shown to reduce propofol injection pain", but subjects in this study received variable oral benzodiazepine premedication, which may have influenced reporting of discomfort. In the present study a larger dose of metoclopramide was added directly to room temperature propofol, and then the mixture used to induce unpremedicated patients.
In addition to assessing injection pain, both after a test dose and on direct questioning half-way through induction, possible adverse effects of metoclopramide were also assessed (residual sedation, extrapyramidal reactions, local and haemodynamic reactions) as well as any favourable effect on nausea and vomiting.
An incidence of injection pain comparable to that seen with the use of lignocaine was found when metoclopramide was mixed with propofo!. When severe pain was seen after a test dose, the addition of lignocaine reduced subsequent pain.
Although crudely assessed, no residual sedation was noted in patients receiving metoclopramide, though it is possible that sensitive psychometric tests may have found a subtle inter-group difference.
It proved difficult to differentiate between "extrapyramidal" phenomena seen with metoclopramide and similar signs observed with propofol itselp6. This adverse effect may have been under-reported. No specific intervention was required in the single patient who had a definite increase in muscle tone.
A significant reduction in nausea, but not in vomiting, was noted in those receiving metoclopramide. Delayed nausea and vomiting were not assessed.
Patients were equally happy with either drug combination, in contrast to the finding of Newcombe that 29070 of those who received saline-propofol would refuse to have the same anaesthetic again. Adding metoclopramide rather than lignocaine to propofol may be a reasonable alternative, especially when an anti-reflux/anti-nausea agent is indicated.
